AUPH
HealthcareAurinia Pharmaceuticals Inc.
$15.30
$-0.05 (-0.33%)
Jan 5, 2026
Price History (1Y)
Analysis
Aurinia Pharmaceuticals Inc. operates within the healthcare sector and biotechnology industry. The company has a market capitalization of $2.02 billion, indicating a significant scale in the industry. Aurinia also employs 130 individuals, further emphasizing its size. From a financial perspective, Aurinia demonstrates strong profitability with gross margin, operating margin, and profit margin standing at 80.2%, 40.5%, and 29.3% respectively. The company's returns on equity (ROE) and return on assets (ROA) are 20.7% and 9.4% respectively. Additionally, the debt-to-equity ratio is 21.38 and the current ratio is 5.76, indicating manageable leverage and liquidity. In terms of valuation, Aurinia's price-to-earnings (P/E) ratio on a trailing twelve-month basis is 27.32, while its forward P/E is 16.36. Revenue growth has been steady at 8.4% year-over-year, with earnings growth reaching as high as 130%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Visit website →Key Statistics
- Market Cap
- $2.02B
- P/E Ratio
- 27.32
- 52-Week High
- $16.54
- 52-Week Low
- $6.55
- Avg Volume
- 1.53M
- Beta
- 1.47
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- Canada
- Employees
- 130